Tumour Ploidy and Survival in Advanced Breast Cancer
Author Information
Author(s): R. Stuart-Harris, D.W. Hedley, I.W. Taylor, A.L. Levene, I.E. Smith
Primary Institution: Ludwig Institute for Cancer Research (Sydney Branch)
Hypothesis
Does cellular DNA content influence the survival of patients with advanced breast cancer receiving endocrine therapy?
Conclusion
The study found no significant survival advantage for patients with diploid tumours compared to those with aneuploid tumours receiving endocrine therapy.
Supporting Evidence
- 31 out of 42 tumour samples were aneuploid, and 11 were diploid.
- Patients with aneuploid tumours had a median survival of 19+ months compared to 11 months for diploid tumours.
- 42% of patients with aneuploid tumours achieved objective response or disease stabilisation compared to 18% of those with diploid tumours.
Takeaway
This study looked at how the DNA content of breast cancer tumours affects how long patients live after treatment. It found that having a certain type of tumour DNA didn't help patients live longer.
Methodology
Flow cytometric analysis of paraffin-embedded tumour samples from patients with advanced breast cancer was used to assess cellular DNA content and its relationship with survival.
Potential Biases
The study may be subject to selection bias due to the small number of patients and the specific criteria for inclusion.
Limitations
The study had a small sample size and low statistical power, making it difficult to draw definitive conclusions.
Participant Demographics
Patients included were those with symptomatic, locally recurrent or metastatic breast cancer, with a mix of menopausal statuses.
Statistical Information
P-Value
P=NS
Confidence Interval
95% confidence intervals - 49%, 7%
Want to read the original?
Access the complete publication on the publisher's website